ERF Stock Analysis: Eurofins Scientific SE | PA
Diagnostics & Research | PA, France | Market Cap: 11.424m EUR | 12M Return: 3.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 16.4M
EPS Trend: -10.6%
Rev. Trend: 80.5%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Eurofins Scientific SE (PA: ERF) is a Luxembourg-headquartered provider of analytical testing and laboratory services operating a global network of laboratories. Founded in 1987, the company serves clients across multiple end markets through service lines that include agroscience, agro testing, biopharma, clinical diagnostics, consumer product testing, cosmetics and personal care, electrical and electronics, environment testing, food and feed testing, forensic, genomic, materials and engineering, maritime, and sensory/consumer research, as well as REACH services and in vitro diagnostics.
The business model is built on fee-for-service testing, audits, certifications, and laboratory insourcing solutions sold to regulated industries such as pharmaceuticals, food producers, environmental agencies, and consumer goods manufacturers, which gives the group a contract-based, recurring revenue profile. Eurofins is classified under the GICS Health Care sector and Biotechnology sub-industry, and is a large-cap stock with a market capitalisation of approximately $12.4 billion.
- Food and feed testing demand grows on tightening safety regulations
- Operating margin expansion from network optimization and lab consolidation
- Biopharma and clinical diagnostics acquisitions drive revenue diversification
| Net Income: 530.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.20 > 1.0 |
| NWC/Revenue: 4.43% < 20% (prev 7.47%; Δ -3.04% < -1%) |
| CFO/TA 0.12 > 3% & CFO 1.36b > Net Income 530.4m |
| Net Debt (5.29b) to EBITDA (1.49b): 3.55 < 3 |
| Current Ratio: 1.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (183.7m) vs 12m ago -5.89% < -2% |
| Gross Margin: 11.97% > 18% (prev 22.59%; Δ -10.62% > 0.5%) |
| Asset Turnover: 68.08% > 50% (prev 67.49%; Δ 0.59% > 0%) |
| Interest Coverage Ratio: 4.98 > 6 (EBIT TTM 918.7m / Interest Expense TTM 184.4m) |
| A: 0.03 (Total Current Assets 2.81b - Total Current Liabilities 2.49b) / Total Assets 11.1b |
| B: 0.29 (Retained Earnings 3.17b / Total Assets 11.1b) |
| C: 0.08 (EBIT TTM 918.7m / Avg Total Assets 10.8b) |
| D: 0.49 (Book Value of Equity 3.62b / Total Liabilities 7.46b) |
| Altman-Z'' = 2.20 = BBB |
| DSRI: 1.08 (Receivables 1.55b/1.40b, Revenue 7.38b/7.14b) |
| GMI: 1.89 (GM 22.59% / 11.97%) |
| AQI: 0.96 (AQ_t 0.50 / AQ_t-1 0.52) |
| SGI: 1.03 (Revenue 7.38b / 7.14b) |
| TATA: -0.08 (NI 530.4m - CFO 1.36b) / TA 11.1b) |
| Beneish M = -2.17 (Cap -4..+1) = BB |
As of July 29, 2026, the stock is trading at EUR 66.92 with a total of 268,955 shares traded. Over the past week, the price has changed by -5.88%, over one month by -1.85%, over three months by +10.03% and over the past year by +3.50%.
Current recommended Stop Loss: 64.40 (which is 3.8% or 1.4 ATR below the current price).
Eurofins Scientific SE has no consensus analysts rating.
P/E Trailing = 25.9294
P/E Forward = 17.6367
P/S = 1.5658
P/B = 2.6842
P/EG = 1.0746
Revenue TTM = 7.38b EUR
EBIT TTM = 918.7m EUR
EBITDA TTM = 1.49b EUR
Long Term Debt = 3.41b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 772.0m EUR (from shortTermDebt, last quarter)
Debt = 5.91b EUR (from shortLongTermDebtTotal, last quarter) + Leases 435.9m
Net Debt = 5.29b EUR (calculated: Debt 5.91b - CCE 618.0m)
Enterprise Value = 16.7b EUR (11.4b + Debt 5.91b - CCE 618.0m)
Interest Coverage Ratio = 4.98 (Ebit TTM 918.7m / Interest Expense TTM 184.4m)
EV/FCF = 26.33x (Enterprise Value 16.7b / FCF TTM 634.9m)
FCF Yield = 3.80% (FCF TTM 634.9m / Enterprise Value 16.7b)
FCF Margin = 8.60% (FCF TTM 634.9m / Revenue TTM 7.38b)
Net Margin = 7.18% (Net Income TTM 530.4m / Revenue TTM 7.38b)
Gross Margin = 11.97% ((Revenue TTM 7.38b - Cost of Revenue TTM 6.50b) / Revenue TTM)
Gross Margin QoQ = 13.48% (prev 10.45%)
Tobins Q-Ratio = 1.50 (Enterprise Value 16.7b / Total Assets 11.1b)
Interest Expense / Debt = 3.12% (Interest Expense 184.4m / Debt 5.91b)
Taxrate = 27.44% (199.4m / 726.8m)
NOPAT = 666.7m (EBIT 918.7m * (1 - 27.44%))
Current Ratio = 1.13 (Total Current Assets 2.81b / Total Current Liabilities 2.49b)
Debt / Equity = 1.63 (Debt 5.91b / totalStockholderEquity, last quarter 3.62b)
Debt / EBITDA = 3.55 (Net Debt 5.29b / EBITDA 1.49b)
Debt / FCF = 8.33 (Net Debt 5.29b / FCF TTM 634.9m)
Total Stockholder Equity = 4.28b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.89% (Net Income 530.4m / Total Assets 11.1b)
RoE = 12.38% (Net Income TTM 530.4m / Total Stockholder Equity 4.28b)
RoCE = 11.94% (EBIT 918.7m / Capital Employed (Equity 4.28b + L.T.Debt 3.41b))
RoIC = 7.39% (NOPAT 666.7m / Invested Capital 9.02b)
WACC = 5.08% (E(11.4b)/V(17.3b) * Re(6.53%) + D(5.91b)/V(17.3b) * Rd(3.12%) * (1-Tc(0.27)))
Discount Rate = 6.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -93.24 | Cagr: -3.32%
[DCF] Terminal Value 75.63% ; FCFF base≈631.3m ; Y1≈641.4m ; Y5≈695.7m
[DCF] Fair Price = 31.85 (EV 10.8b - Net Debt 5.29b = Equity 5.50b / Shares 172.8m; r=8.35% [WACC [floored]]; 5y FCF grow 1.42% → 2.50% )
EPS Correlation: -10.59 | EPS CAGR: -1.50% | SUE: N/A | # QB: 0
Revenue Correlation: 80.55 | Revenue CAGR: 14.34% | SUE: 1.18 | # QB: 1
EPS current Quarter (2026-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=4.01 | Chg30d=+0.43% | Revisions=+40% | GrowthEPS=+3.1% | GrowthRev=+4.2%
EPS next Year (2027-12-31): EPS=4.65 | Chg30d=-0.16% | Revisions=+40% | GrowthEPS=+15.9% | GrowthRev=+6.1%
[Analyst] Revisions Ratio: +57% (up=4, down=0)